Nektar Therapeutics Stock Probability of Future Stock Price Finishing Under 0.10
| NKTR Stock | USD 1.10 0.14 14.58% |
Nektar |
Nektar Therapeutics Target Price Odds to finish below 0.10
The tendency of Nektar Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.10 or more in 90 days |
| 1.10 | 90 days | 0.10 | near 1 |
Based on a normal probability distribution, the odds of Nektar Therapeutics to drop to $ 0.10 or more in 90 days from now is near 1 (This Nektar Therapeutics probability density function shows the probability of Nektar Stock to fall within a particular range of prices over 90 days) . Probability of Nektar Therapeutics price to stay between $ 0.10 and its current price of $1.1 at the end of the 90-day period is about 34.0 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.02 . This indicates Nektar Therapeutics market returns are sensible to returns on the market. As the market goes up or down, Nektar Therapeutics is expected to follow. Additionally Nektar Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Nektar Therapeutics Price Density |
| Price |
Predictive Modules for Nektar Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nektar Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nektar Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Nektar Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Nektar Therapeutics is not an exception. The market had few large corrections towards the Nektar Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nektar Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nektar Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.19 | |
β | Beta against Dow Jones | 1.02 | |
σ | Overall volatility | 0.17 | |
Ir | Information ratio | -0.05 |
Nektar Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nektar Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nektar Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nektar Therapeutics generated a negative expected return over the last 90 days | |
| Nektar Therapeutics may become a speculative penny stock | |
| Nektar Therapeutics has high historical volatility and very poor performance | |
| Nektar Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 90.12 M. Net Loss for the year was (276.06 M) with profit before overhead, payroll, taxes, and interest of 70.42 M. | |
| Nektar Therapeutics currently holds about 546.39 M in cash with (192.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from newswire.com: Donald Stuart Seigal Aka ANTHEMan Releases New Years Eve Song Party People |
Nektar Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nektar Stock often depends not only on the future outlook of the current and potential Nektar Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nektar Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 190 M | |
| Cash And Short Term Investments | 303.6 M |
Nektar Therapeutics Technical Analysis
Nektar Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Nektar Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Nektar Therapeutics. In general, you should focus on analyzing Nektar Stock price patterns and their correlations with different microeconomic environments and drivers.
Nektar Therapeutics Predictive Forecast Models
Nektar Therapeutics' time-series forecasting models is one of many Nektar Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Nektar Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Nektar Therapeutics
Checking the ongoing alerts about Nektar Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Nektar Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Nektar Therapeutics generated a negative expected return over the last 90 days | |
| Nektar Therapeutics may become a speculative penny stock | |
| Nektar Therapeutics has high historical volatility and very poor performance | |
| Nektar Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 90.12 M. Net Loss for the year was (276.06 M) with profit before overhead, payroll, taxes, and interest of 70.42 M. | |
| Nektar Therapeutics currently holds about 546.39 M in cash with (192.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from newswire.com: Donald Stuart Seigal Aka ANTHEMan Releases New Years Eve Song Party People |
Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.